Correspondence 0000950170-25-053136 from Kyverna Therapeutics, Inc. (KYTX)
Kyverna Therapeutics, Inc.
Date: April 11, 2025 · CIK: 0001994702 · Accession: 0000950170-25-053136
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-286180
Letter
Kyverna Therapeutics, Inc. 5980 Horton St., STE 550 Emeryville, CA 94608 April 11, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-0406 Attention: Lauren Hamill Re: Kyverna Therapeutics, Inc. Registration Statement on Form S-3 Filed March 27, 2025 File No. 333-286180 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Kyverna Therapeutics, Inc. (the “ Company ”) hereby respectfully requests that the effectiveness of the Registration Statement on Form S-3 (File No. 333-286180) of the Company, filed with the Securities and Exchange Commission on March 27, 2025 (the “ Registration Statement ”), be accelerated so that the Registration Statement shall become effective at 4:30 p.m., Eastern Time, on April 15, 2025 or as soon as possible thereafter. The Company hereby confirms that it is aware of its responsibilities under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, as they relate to the proposed offering of the securities specified in the Registration Statement. It would be appreciated if, promptly after the Registration Statement has become effective, you would so inform our outside counsel, Samantha H. Eldredge of Paul Hastings LLP, by telephone at (650) 320-1838 or by email at samanthaeldredge@paulhastings.com. The Company hereby authorizes Ms. Eldredge to orally modify or withdraw this request for acceleration. Sincerely, KYVERNA THERAPEUTICS, INC. By: /s/ Ryan Jones Name: Ryan Jones Title: Chief Financial Officer cc: Samantha H. Eldredge, Esq. (Paul Hastings LLP)
Show Raw Text
CORRESP 1 filename1.htm CORRESP Kyverna Therapeutics, Inc. 5980 Horton St., STE 550 Emeryville, CA 94608 April 11, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-0406 Attention: Lauren Hamill Re: Kyverna Therapeutics, Inc. Registration Statement on Form S-3 Filed March 27, 2025 File No. 333-286180 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Kyverna Therapeutics, Inc. (the “ Company ”) hereby respectfully requests that the effectiveness of the Registration Statement on Form S-3 (File No. 333-286180) of the Company, filed with the Securities and Exchange Commission on March 27, 2025 (the “ Registration Statement ”), be accelerated so that the Registration Statement shall become effective at 4:30 p.m., Eastern Time, on April 15, 2025 or as soon as possible thereafter. The Company hereby confirms that it is aware of its responsibilities under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, as they relate to the proposed offering of the securities specified in the Registration Statement. It would be appreciated if, promptly after the Registration Statement has become effective, you would so inform our outside counsel, Samantha H. Eldredge of Paul Hastings LLP, by telephone at (650) 320-1838 or by email at samanthaeldredge@paulhastings.com. The Company hereby authorizes Ms. Eldredge to orally modify or withdraw this request for acceleration. Sincerely, KYVERNA THERAPEUTICS, INC. By: /s/ Ryan Jones Name: Ryan Jones Title: Chief Financial Officer cc: Samantha H. Eldredge, Esq. (Paul Hastings LLP)